# Wallaby Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/wallaby-medical

- Industry: Medical Devices & Equipment
- Headquarters: Shanghai, China
- Website: www.wallabymedical.com.cn
- Total disclosed funding: $14M
- Latest round: Series C (Mar 18, 2026)
- Investors on record: 15

## About

Based in Shanghai, China and founded in 2016, Shanghai Wallaby Medical Technologies Co., Inc., trading as Wallaby Medical, is a diagnosis and treatment intervention product developer that focuses on cerebrovascular disease, providing cerebrovascular patients with neuromedical products. In March 2026, Wallaby Medical closed Series C+ funding co-led by Gaorong Ventures, Hillhouse Investment, YF Capital, Huajie Gaojing Management Consulting (Beijing), Junson Capital and Qianhai Ark Capital, with participation from Enlight Medical Technologies (Shanghai) Co., Ltd.,

The company’s main business is researching, developing, and manufacturing interventional products for cerebrovascular diseases. The company’s self-developed products include Avenir mechanical detachment coils, p64/p48 flow - directed devices, pEGASUS coil-assisted embolization stents, etc. Its products are used in the field of hemorrhagic stroke, ischemic stroke, and access.
The company generates revenue by providing cerebrovascular disease treatment products and solutions to customers in over 60 countries and regions worldwide.
The Series C+ funding raised in March 2026 will be used to accelerate the overseas clinical registration and domestic commercialization of its core products, as well as the development of a next-generation thrombectomy platform.

## Funding rounds

- Series C, Mar 18, 2026 — YF Capital, Hillhouse Investment, Gaorong Ventures, Junson Capital, Qianhai Ark Capital, Enlight Medical Technologies (Shanghai) Co., Ltd., Huajie Gaojing Management Consulting (Beijing)
- Series C, Nov 24, 2020 — Sinovation Ventures, CareCapital, GL Ventures
- Series B, Aug 11, 2020, $14M — Chang'an Capital, Maison Capital, Qianhai Ark Capital, CITIC Med Fund
- Series B, Nov 3, 2018 — Chang'an Capital, Qianhai Ark Capital
- Series A, Dec 11, 2017 — Detong Capital, CD Capital

## Investors

- Detong Capital (https://capitalatlas.ai/funds/detong-capital) — Series A
- CD Capital — Series A
- Chang'an Capital (https://capitalatlas.ai/funds/chang-an-capital) — Series B
- Qianhai Ark Capital (https://capitalatlas.ai/funds/qianhai-ark-capital) — Series B, Series C
- Maison Capital (https://capitalatlas.ai/funds/maison-capital) — Series B
- CITIC Med Fund (https://capitalatlas.ai/funds/citic-med-fund) — Series B
- Sinovation Ventures (https://capitalatlas.ai/funds/sinovation-ventures) — Series C
- CareCapital (https://capitalatlas.ai/funds/carecapital) — Series C
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series C
- YF Capital (https://capitalatlas.ai/funds/yf-capital) — Series C
- Hillhouse Investment (https://capitalatlas.ai/funds/hillhouse-investment) — Series C
- Gaorong Ventures (https://capitalatlas.ai/funds/gaorong-ventures) — Series C
- Junson Capital — Series C
- Enlight Medical Technologies (Shanghai) Co., Ltd. — Series C
- Huajie Gaojing Management Consulting (Beijing) — Series C